(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 July 2008 (03.07.2008)

PCT

(10) International Publication Number
WO 2008/077591 A3

(51) International Patent Classification:
A61K 9/14 (2006.01) *A61K 31/55* (2006.01)
A61K 9/16 (2006.01) *A61K 31/4468* (2006.01)

(21) International Application Number:
PCT/EP2007/011293

(22) International Filing Date:
20 December 2007 (20.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06126964.3 22 December 2006 (22.12.2006) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DIEDERICH, Anke** [DE/CH]; St. Alban-Vorstadt 98, CH-4052 Basel (CH). **TIMPE, Carsten** [DE/DE]; Haydnweg 21, 79395 Neuenburg (DE). **RIES, Angelika** [DE/CH]; Blauenweg 10, CH-4224 Nenzlingen (CH). **OTTINGER, Isabel** [DE/DE]; Maria-Föhrenbach-Stasse 7, 79111 Freiburg (DE). **MUELLER, Irene** [DE/DE]; Vogesenring 11, 79219 Staufen (DE). **HERBIG, Michael** [DE/CH]; Gundeldingerstrasse 492, CH-4053 Basel (CH). **SCHUETZ, Helmut** [DE/DE]; Lenbachstr. 4, 79618 Rheinfelden (DE). **LAKSHMAN, Jay Parthiban** [US/US]; 169 Candlewick Lane, Bridgewater, New Jersey 08807 (US). **KALB, Oskar** [DE/DE]; Belchenstrasse 9, 79539 Lörrach (DE).

(74) Agent: **BARBIER, Denis**; Novartis Pharma AG, Patent Department, Postfach, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
9 April 2009

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING NEUROKININ ANTAGONIST

(57) Abstract: Solid dispersion comprising (4R)-4-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide or a pharmaceutically acceptable salt or solvate thereof and a carrier. Pharmaceutical compositions comprising such solid dispersion are useful to treat patients who have functional motility disorders of the viscera, especially irritable bowel syndrome or functional dyspepsia, or urinary bladder disorders, especially urinary incontinence.

WO 2008/077591 A3